MedTrace Logo

BCAAs in Concussion 3.0

NCT07670195 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2026-09-03

No results posted yet for this study

Summary

This study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (BCAAs) in the treatment of concussion. The aim of the study is to determine whether administration of high-dose BCAAs compared to placebo promotes concussion recovery.

Conditions

  • Concussion (Diagnosis)
  • MTBI - Mild Traumatic Brain Injury
  • Concussion, Brain
  • Concussion

Interventions

DRUG

BCAA

The three BCAAs will be combined together into a powder formulation.

OTHER

Placebo

The placebo formulation will have similar taste, texture, consistency and appearance as the BCAA formulation.

Sponsors & Collaborators

  • Akiva Cohen

    lead OTHER

Principal Investigators

  • Daniel Corwin, MD · Children's Hospital of Philadelphia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
11 Years
Max Age
23 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-05
Primary Completion
2027-06-30
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07670195 on ClinicalTrials.gov